The FDA decision on Filgotinib, proposed for the treatment of moderate-to-severe rheumatoid arthritis in adults, is expected on August 19, 2020.Filgotinib, an oral selective JAK1 inhibitor, is being developed by Gilead Sciences and Belgian company Galapagos NV (GLPG). In December 2015, Gilead entered into a global partnership to jointly develop Filgotinib in a deal potentially valued at over $2.075 billion. Last July, the two companies inked a 10-year global research and development collaboration. Under that deal, Gilead made an upfront payment of $3.95 billion and equity investment of $1.1 billion.Filgotinib has the potential to achieve blockbuster status, according to analysts.The approved rheumatoid arthritis drugs belonging to the class of JAK inhibitors include Eli Lilly’s Olumiant, Pfizer’s Xeljanz and AbbVie’s Rinvoq.GLPG closed Friday’s (Jul.24, 2020) trading at $193.65, down 3.37%.